TB-500 legal status leaves pharmacy use unsettled
The laboratory copy was made for repair studies. People later proposed pharmacy use. FDA advisers discussed the proposal in July 2026, leaving your treatment question unsettled.
What July 2026 discussion left open about TB-500 legal status
People asked FDA to consider TB-500 for pharmacy-made medicines. The notices don’t name those people. FDA advisers discussed proposed ingredients during July 23-24, 2026. The agenda named TB-500 free base and TB-500 acetate. The two forms differ by the addition of an acid. The free base has no added acid. The acetate has the acid found in vinegar attached. That difference concerns the ingredient a pharmacy would mix. Neither form has FDA approval for treating you. Both forms were considered for pharmacy use [18]. BPC-157 also appeared on the agenda [18]. FDA staff advised against adding TB-500 to the permitted-ingredient list. That was advice to the decision makers, rather than a final refusal. By September 2026, FDA hadn't published how the advisers voted.
Discussion alone can't give your pharmacist permission.
The meeting didn't settle whether pharmacies could mix TB-500 medicines [18]. FDA makes the final decision about the permitted ingredients. The advisers give FDA their views as part of that review [19]. The July 2026 agenda doesn't establish the final answer [18].
A permitted ingredient may be used for certain patients' specially mixed medicines. That permission doesn't mean FDA approved each finished medicine. No finished medicine containing TB-500 has received approval. Pharmacy permission remains unsettled as well. Your medical or legal case needs personal advice. No medicines are sold or supplied here.
What Category 2 meant before the proposal was withdrawn
FDA flagged the thymosin beta-4 part called TB-500 for safety concerns. Category 2 grouped proposed pharmacy ingredients that might cause serious harm. The warning appeared in the list dated September 29, 2023. FDA warned that the immune system, the body’s defenses, might react against treatment. That reaction could make people ill. The warning referred to certain ways of giving treatment without naming them. You can't tell from that warning whether a proposed shot is covered. FDA also lacked important safety information [20]. The entry identifies TB-500 as part of thymosin beta-4 [20].
A withdrawn proposal didn't answer those safety questions.
FDA's page current as of April 22, 2026 shows the proposal as withdrawn. TB-500 isn't in Category 2 on that page. Category 2 had been a warning group, not a permitted-ingredient list. The people who proposed TB-500 for pharmacy use withdrew their request. Those people aren’t named here. FDA says these withdrawn proposals had previously been in Category 2. The safety concerns remain displayed [19]. Withdrawal didn't grant approval or pharmacy permission. The later advisers’ meeting still wasn’t a final decision. FDA hasn't explained what pharmacies may do after the withdrawal [20].
FDA drug approval examines a finished medicine's benefits, harms, and quality. TB-500 has no such approval. A different set of rules governs ingredients used by pharmacies. Those rules concern mixing medicine, rather than writing a prescription. The ingredient question remains unanswered after withdrawal [19][20]. You can't treat an unanswered question as permission.
What your doctor and pharmacist need to explain
Specially mixed medicines can serve patients with particular needs. A licensed prescriber first assesses whether that medicine fits the patient. Prescribers are licensed to write prescriptions. A valid prescription identifies the particular patient who needs treatment [21]. A state-licensed pharmacy then prepares the medicine. Larger supplies can come from a drug-making facility listed with FDA. Such facilities must follow rules for making good-quality medicines [21].
Your prescription doesn’t settle permission to use the ingredient.
An assessment can happen by telephone or video. Your prescriber has to examine both your health and the treatment proposed. Responsibility for the assessment and prescription remains with that prescriber [21]. Ingredient rules still apply, even after a video visit.
Pharmacy ingredients must qualify under one of the legal rules. Some qualify through an entry in official drug-ingredient books. Those entries describe ingredients and the tests for their quality. Ask your pharmacist which entry applies to the medicine. An ingredient from a drug approved by FDA may qualify under another rule. That rule concerns the ingredient; the new mixture doesn't gain drug approval. A further route is FDA's list of permitted pharmacy ingredients [19]. TB-500's safety concerns remain displayed after the proposal was withdrawn. FDA hasn't settled what the pharmacy may do with that change [21].
Ask your prescriber and pharmacist which rule permits the ingredient. They need to explain how the proposed medicine meets that rule. A prescription alone doesn't provide the full answer. These facts don't establish treatment amounts or endorse a clinic.
What approval and pharmacy mixing each require
A clinic may mention pharmacy permission when describing treatment. Permission to mix a patient's medicine differs from FDA drug approval. FDA approval concerns the finished medicine's benefits, harms, and quality. You need to know which claim the clinic is making. No later FDA decision is assumed in these answers.
Is TB-500 FDA approved?
TB-500 hasn't received FDA approval for treating people. FDA placed the thymosin beta-4 part called TB-500 in Category 2. That group warned of serious safety risks from proposed pharmacy ingredients. The warning list was dated September 29, 2023. FDA feared an immune system reaction could cause illness. The warning mentioned certain ways of giving treatment without naming them. A patient considering shots can't tell which ways the warning covers. Important facts about safety were also missing [20].
What changes TB-500 rules where you live?
The answer depends on country and intended use. In 2023, FDA placed TB-500 in Category 2 because of safety concerns. The pharmacy-use proposal later appeared as withdrawn. The agency hasn't explained whether pharmacies may mix TB-500 after withdrawal. There isn't an approved use for treating patients [19][20]. WADA separately prohibits TB-500 use by athletes [22]. Your legal question needs advice for your location and intended use.
What must happen before a pharmacy supplies TB-500?
You need an assessment and valid prescription from a licensed prescriber. A licensed pharmacy or drug-making facility listed with FDA must prepare the medicine [21]. Those steps don't settle whether the ingredient is permitted. FDA still shows the withdrawn TB-500 proposal and its safety concerns. Withdrawal hasn't been declared permission to mix medicines with the ingredient [19][21]. Ask which ingredient rule the pharmacy relies on.
What did FDA’s TB-500 warning mean for penalties?
FDA placed the thymosin beta-4 part called TB-500 in Category 2. That warning group covered ingredients with possible serious safety risks. The list was dated September 29, 2023. The proposal appears withdrawn on FDA's page current as of April 22, 2026 [20]. FDA temporarily held off penalties for some ingredients awaiting review. Category 2 ingredients didn't receive that protection from penalties. Pharmacies mixing those ingredients could still face action by FDA. Holding off penalties for other ingredients didn't approve the finished medicines. FDA hasn't explained how withdrawn proposals fit those penalty rules [19]. TB-500 was discussed at the July 23-24, 2026 meeting. The advisers’ votes weren’t public, leaving the pharmacy question unsettled [18].